Different studies have also shown the usefulness of DPP-4 inhibitors (linagliptin) both in preventing T2D in patients with prediabetes20, and in reducing insulin requirements and improving metabolic control in patients with in-hospital hyperglycemia after kidney transplantation when combined with insulin16, and they are mainly indicated for uncontrolled patients with T2D who do not meet glucose control21,22. The gene discussed is INS; the disease is Hyperglycemia.